Trials / Available
AvailableNCT06931834
Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease
Expanded Access Treatment Protocol for R007 (Probucol) Tablets in Adults With Genetically-Confirmed Mitochondrial Disease and Chronic Kidney Disease (Intermediate-Size Patient Population)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- RiboNova Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this expanded access program is to enable access to R007 (probucol) tablets for the compassionate treatment of adults with mitochondrial disease who also have chronic kidney disease.
Detailed description
The protocol for this expanded access program provides for the compassionate treatment with R007 (probucol) tablets of adults who (i) have serious or life-threatening mitochondrial disease and also have chronic kidney disease stages 3 or 4, (ii) do not have access to a satisfactory alternative therapy to treat their condition, and (iii) are not able to enroll in a clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Probucol | Probucol 250 mg tablets orally up to a daily dose of 1,000 mg |
Timeline
- First posted
- 2025-04-17
- Last updated
- 2025-04-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06931834. Inclusion in this directory is not an endorsement.